A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety, Tolerability, And Efficacy Of Cilofexor In Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis
Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Inactive
The primary objective of this study is to evaluate whether Cilofexor (CILO), (previously known as GS-9674) reduces the risk of fibrosis progression among non-cirrhotic subjects with Primary Sclerosing Cholangitis (PSC).
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.